Genomic Organization & Cytogenetic Locus: 9-exon gene on chromosome 10q21.3 encoding the largest human sirtuin (747 amino acids), featuring a conserved 275-residue Rossmann-fold NAD+-binding and Zn2+-ribbon catalytic core flanked by extended intrinsically disordered N-terminal (containing the STAC allosteric binding domain at Glu230) and C-terminal regulatory regions (containing the essential-for-SIRT1-activity ESA motif).
Cellular & Tissue Expression Profile: Predominantly nuclear (with nucleocytoplasmic shuttling signals) in hepatic hepatocytes, skeletal muscle fibers, cardiac myocytes, white and brown adipocytes, vascular endothelial cells, and hypothalamic arcuate/suprachiasmatic nucleus neurons.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Couples protein lysine deacetylation directly to cellular metabolic state by cleaving one molecule of oxidized NAD+ per acetyl group removed, yielding deacetylated lysine, nicotinamide (recycled by NAMPT), and 2-prime-O-acetyl-ADP-ribose; during fasting and aerobic exercise when NAD+ rises, SIRT1 deacetylates and activates PGC-1alpha (PPARGC1A) to drive mitochondrial biogenesis, deacetylates FOXO1 and FOXO3 to shift transcription toward antioxidant (SOD2, catalase) and autophagic programs, deacetylates PPARG to induce beige adipose UCP1, deacetylates RelA/p65 (NFKB) to suppress inflammation, and deacetylates p53 (at Lys382) to prevent premature senescence.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Human SIRT1 promoter and intronic polymorphisms correlate with energy expenditure, visceral adiposity, and cardiovascular aging, while redistribute-to-breaks recruitment of SIRT1 to DNA double-strand breaks (which transiently depletes SIRT1 from homeostatic promoters during aging) is a core mechanism of the "relocalization of chromatin modifiers" (RCM) theory of epigenetic aging.
Therapeutic & Clinical Pharmacology: Allosterically activated via its N-terminal Glu230 domain by natural polyphenols (resveratrol) and synthetic sirtuin-activating compounds (SRT1720, SRT2104) and substrate-supported by NAD+ precursors (NMN, NR) and CD38 inhibitors.